Literature DB >> 24674271

Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome.

Johannes Ehler1, Sebastian Koball, Martin Sauer, Heiko Hickstein, Steffen Mitzner, Reiner Benecke, Uwe K Zettl.   

Abstract

Clinically Isolated Syndromes (CIS) summarize clinical features of possible multiple sclerosis (MS) as a first clinical event of the disease. Escalation therapy in CIS episodes comprises high dose glucocorticosteroid (GCS) treatment followed by therapeutic plasma exchange (TPE) in patients unresponsive to GCS. The aim of our study was to analyze TPE effects in CIS patients. Eleven GCS-unresponsive patients exhibiting CIS were treated with TPE. A median of 5.0 (range 3-8) treatments were performed with a median exchange volume of 3.0 L (range 2.2-3.5 L). Standard diagnostic results in CIS patients were collected. In 10 out of 11 patients clinical improvement was observed. In Expanded Disability Status Scale (EDSS) Scoring, a commonly used score to assess disability in MS and CIS patients, significant improvement was shown as well. One patient was a non-responder to TPE. Apheresis treatments were well tolerated in all patients. In the medical control of GCS-unresponsive CIS episodes, TPE appears to be an effective and well-tolerated treatment option. TPE response in CIS patients is comparable to TPE results in GCS-unresponsive MS relapses. Further prospective studies are indicated.
© 2014 The Authors. Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis.

Entities:  

Keywords:  Apheresis; Escalation therapy; Multiple sclerosis; Neuroimmunology; Steroid-refractory

Mesh:

Substances:

Year:  2014        PMID: 24674271     DOI: 10.1111/1744-9987.12176

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  11 in total

Review 1.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

2.  Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

Authors:  P S Rommer; T Dörner; K Freivogel; J Haas; B C Kieseier; T Kümpfel; F Paul; F Proft; H Schulze-Koops; E Schmidt; H Wiendl; U Ziemann; U K Zettl
Journal:  J Neuroimmune Pharmacol       Date:  2015-11-20       Impact factor: 4.147

3.  Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis.

Authors:  Nic Skorupka; Andrei Miclea; Katarzyna Aleksandra Jalowiec; Christoph Bocksrucker; Nicole Kamber; Andrew Chan; Behrouz Mansouri Taleghani; Robert Hoepner; Anke Salmen
Journal:  Transfus Med Hemother       Date:  2019-11-14       Impact factor: 3.747

4.  The chronically inflamed central nervous system provides niches for long-lived plasma cells.

Authors:  Karolin Pollok; Ronja Mothes; Carolin Ulbricht; Alina Liebheit; Jan David Gerken; Sylvia Uhlmann; Friedemann Paul; Raluca Niesner; Helena Radbruch; Anja Erika Hauser
Journal:  Acta Neuropathol Commun       Date:  2017-11-25       Impact factor: 7.801

5.  Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.

Authors:  Johannes Ehler; Stephan Blechinger; Paulus S Rommer; Sebastian Koball; Steffen Mitzner; Hans-Peter Hartung; Fritz Leutmezer; Martin Sauer; Uwe K Zettl
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

6.  Pathophysiological changes of inflammatory syndrome in multiple sclerosis after instituting therapeutic plasmapheresis.

Authors:  S Vlaic; V Poalelungi; M Bălăeţ; V L Purcărea; C Bălăeţ; B I Coculescu
Journal:  J Med Life       Date:  2017 Jan-Mar

Review 7.  Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.

Authors:  Klaus Lehmann-Horn; Silke Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2017-09-23       Impact factor: 5.923

Review 8.  Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review.

Authors:  Leoni Rolfes; Steffen Pfeuffer; Tobias Ruck; Nico Melzer; Marc Pawlitzki; Michael Heming; Marcus Brand; Heinz Wiendl; Sven G Meuth
Journal:  J Clin Med       Date:  2019-10-04       Impact factor: 4.241

9.  Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.

Authors:  Johannes Ehler; Sebastian Koball; Martin Sauer; Steffen Mitzner; Heiko Hickstein; Reiner Benecke; Uwe K Zettl
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

10.  Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis.

Authors:  Mark Lipphardt; Manuel Wallbach; Michael J Koziolek
Journal:  J Clin Med       Date:  2020-05-25       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.